Evotec SE EVT.DE
Composite 27/100; the shares have moved about 61% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 4/100 — a strong mark against it.
Balance-sheet strength ranks 70/100 — a moderate point in its favour.
Growth ranks 4/100 — a strong mark against it. Quality ranks 5/100 — a strong mark against it. Momentum ranks 8/100 — a strong mark against it.
What the company does Evotec SE is a drug discovery and development firm focused on multiple therapeutic areas, including oncology, diabetes, and rare diseases, with over 60 academic and industry partnerships.
Key financials Evotec posts negative profitability: ROE -24.1%, ROA -3.1%, ROCE -11.2%, gross margin 10.7%, operating margin -29.6%, net margin -26.0%. Revenue fell -21.7% while EPS rose 190.9%.
Stock health Momentum is deeply negative: -33.78% over 3m, -44.64% over 6m, -52.97% over 12m, and -53.10% from the 52-week high. RSI(14) is 26.30, indicating oversold conditions.
Price vs fair value The stock trades at a PREMIUM of 72.30% versus our fair-value estimate and at a discount of 41.21% versus the analyst 12-month target. - Negative profitability metrics (ROE -24.1%, ROA -3.1%) (Key financials) - Weak momentum with 12-month return of -52.97% (Momentum) - High valuation multiples: forward P/E 54.35, EV/EBITDA 34.36 (Valuation & Key financials) - Low quality score of 12.8/100 (SIDERAVIA Quality 12.8)
Looking forward Analysts set a 12-month target of €4.90, implying 41.21% upside from the current price, while our fair-value estimate implies a 72.30% premium, suggesting differing views on recovery timing and pipeline success.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.